Abstract
Background Whole-genome sequencing (WGS) data is available from several large studies across a variety of diseases and traits. However, massive storage and computation resources are required to use these data, and, to achieve the sufficient power for discoveries, harmonization of multiple cohorts is critical.
Objectives The Accelerating Medicines Partnership Parkinson’s Disease (AMP PD) program has developed a research platform for Parkinson’s disease (PD) which integrates the storage and analysis of WGS data, RNA expression data, and clinical data, harmonized across multiple cohort studies.
Methods The version 1 release contains WGS data derived from 3,941 participants from 4 cohorts. Samples underwent joint genotyping by the TOPMed Freeze 9 Variant Calling Pipeline. We performed descriptive analyses of these WGS data using the AMP PD platform.
Results The clinical diagnosis of participants in version 1 release includes 2,005 idiopathic PD patients, 963 healthy controls, 64 prodromal subjects, 62 clinically diagnosed PD subjects without evidence of dopamine deficit (SWEDD) and 705 participants of genetically enriched cohorts carrying PD risk associated GBA variants or LRRK2 variants in which 304 were affected. We did not observe a significant enrichment of pathogenic variants in the idiopathic PD group, but the polygenic risk score (PRS) was higher in PD both in non-genetically enriched cohorts and genetically enriched cohorts. The population analysis showed a correlation between genetically enriched cohorts and Ashkenazi Jewish ancestry.
Conclusions We describe the genetic component of the AMP PD platform, a solution to democratise data access and analysis for the PD research community.
Competing Interest Statement
Andrew Singleton received Michael J Fox Foundation for Parkinson's Research (Grant), Department of Defense NETPR Program (Grant IAA-XAG16001-001-00000) Sonja W. Scholzreceived Intramural Research Program of the National Institute of Health (National Institute on Aging, National Institute of Neurological Disorders and Stroke; project numbers: 1ZIAAG000935, 1ZIANS003154).
Clinical Trial
This is not a clinical trials or prospective studies.
Funding Statement
Accelerating Medicines Partnership in Parkinson's Disease (AMP PD), a public-private partnership managed by the FNIH and funded by Celgene, GSK, the Michael J. Fox Foundation for Parkinson's Research, the National Institute of Neurological Disorders and Stroke, Pfizer, Sanofi, and Verily. This work was supported in part by the Intramural Research Program of the National Institute on Aging, National Institutes of Health, Department of Health and Human Services; project ZO1 AG000949 and grants from the Department of Defense (IAA-XAG16001-001-00000), and the Michael J Fox Foundation for Parkinson's Research. This research was supported in part by the Intramural Research Program of the National Institutes of Health (National Institute on Aging, National Institute of Neurological Disorders and Stroke; project numbers: 1ZIAAG000935, 1ZIANS003154).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Participants' clinical information and genetic samples were obtained under appropriate written consent and with local institutional and ethical approvals. The details of these studies can be obtained from the AMP PD website (https://amp-pd.org) and each study website. The data from SURE-PD and STEADY-PD are being processed for the next release.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding sources for study: Accelerating Medicines Partnership in Parkinson’s Disease (AMP PD), a public-private partnership managed by the FNIH and funded by Celgene, GSK, the Michael J. Fox Foundation for Parkinson’s Research, the National Institute of Neurological Disorders and Stroke, Pfizer, Sanofi, and Verily.
This work was supported in part by the Intramural Research Program of the National Institute on Aging, National Institutes of Health, Department of Health and Human Services; project ZO1 AG000949 and grants from the Department of Defense (IAA-XAG16001-001-00000), and the Michael J Fox Foundation for Parkinson’s Research.
This research was supported in part by the Intramural Research Program of the National Institutes of Health (National Institute on Aging, National Institute of Neurological Disorders and Stroke; project numbers: 1ZIAAG000935, 1ZIANS003154).
Data Availability
All data processing was conducted on the Google Cloud Platform. Processing/analysis scripts were provided at the related workspaces for reference. (Accessible for AMP PD users) The resulting CRAM files, VCFs and jointly genotyped data (BCF, VCF, PLINK and BigQuery format) are available through the AMP PD.
